Grant Number:	5R50CA221836-09 Interpret this number
Primary Investigator:	Gulati, Roman
Organization:	Fred Hutchinson Cancer Center
Project Title:	Statistical Modeling to Support Population and Translational Cancer Research
Fiscal Year:	2025

PROJECT SUMMARY/ABSTRACT Developing effective strategies for cancer control requires rigorous analysis of empirical evidence and similarly rigorous analysis to address inevitable gaps in empirical evidence. During the previous project period, the Principal Investigator provided critical statistical support for a broad spectrum of research studies focused on prostate cancer, ranging from basic science experiments through clinical trials and population modeling studies. In this renewal application, he will continue to provide biostatistical analysis services for a multi-project translational prostate cancer research program and computer modeling expertise for a cancer surveillance research program that uses biomathematical models to address evidence gaps and inform population prostate cancer policies. He will also serve as lead modeler in the Data Modeling and Analytics Core of a new multi-project research program that will investigate clinical utility of novel cancer diagnostic technologies and multi-cancer early detection tests. Successfully supporting these research programs requires broad expertise in biostatistical methods, computer programming, and data analysis to identify and implement appropriate methods, interrogate model assumptions, and bracket uncertainty in results. Outstanding scientific collaboration and communication skills are essential to explain strengths and limitations of selected approaches and to bring projects from the scientific inquiry phase through peer review so that their results can impact the delivery of care. During the previous project period, the Principal Investigator consistently demonstrated all these skills and has been instrumental in establishing his research group's leadership in cancer modeling for evidence generation and policy development. Planned studies for the renewal period include modeling of natural history and outcomes for new multi-cancer early detection tests, investigating outcomes of strategies for precision early detection and treatment, and identifying targeted screening and treatment strategies to reduce health disparities. Renewal of the Principal Investigator's Research Specialist award will facilitate his research group's continued stellar level of productivity and foster his continued dissemination of high-impact research characterized by statistical and modeling approaches that are transparent, rigorous, and reliable.




Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.
Authors: Gogebakan K.C. , Elsisi Z. , Montano-Campos F. , Owens L. , Zhao Y. , Gulati R. , Ferdinandus J. , Fendler W.P. , Calais J. , Hope T.A. , et al. .
Source: Cancer, 2025-11-01 00:00:00.0; 131(21), p. e70131.
PMID: 41108673
Related Citations

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.
Authors: Semenova G. , Frank S. , Dumpit R. , Han W. , Coleman I. , Gulati R. , Morrissey C. , Haffner M.C. , Nelson P.S. , Lee J.K. .
Source: Biorxiv : The Preprint Server For Biology, 2025-09-11 00:00:00.0; , .
EPub date: 2025-09-11 00:00:00.0.
PMID: 40964329
Related Citations

Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies.
Authors: Lee H.J. , Gulati R. , Sayar E. , Patel R.A. , Itagi P. , Richards H.M. , Persse T. , Arora S. , Coleman I. , Adil M. , et al. .
Source: Cancer Research Communications, 2025-08-01 00:00:00.0; 5(8), p. 1419-1428.
PMID: 40767528
Related Citations

Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.
Authors: Muchadeyi M.T. , Hao S. , Hernandez-Villafuerte K. , Khan S.A. , Becker N. , Krilaviciute A. , Seibold P. , Gulati R. , Albers P. , Schlander M. , et al. .
Source: International Journal Of Cancer, 2025-07-16 00:00:00.0; , .
EPub date: 2025-07-16 00:00:00.0.
PMID: 40665795
Related Citations

Trends in young-onset cancer incidence: a modeling perspective.
Authors: Owens L. , Fung A. , Shuhendler J. , Glick J. , Ryser M.D. , Gulati R. , Etzioni R. .
Source: Journal Of The National Cancer Institute, 2025-07-01 00:00:00.0; 117(7), p. 1350-1359.
PMID: 40040586
Related Citations

Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer.
Authors: Roudier M.P. , Gulati R. , Sayar E. , Patel R.A. , Tratt M. , Richards H.M. , Cejas P. , Munoz Gomez M. , Qiu X. , Xie Y. , et al. .
Source: The Journal Of Clinical Investigation, 2025-06-10 00:00:00.0; , .
EPub date: 2025-06-10 00:00:00.0.
PMID: 40493417
Related Citations

Sensitivity Measures in Studies of Cancer Early Detection Biomarkers.
Authors: Zhao Y. , Gulati R. , Lange J. , Olivas-Martinez A. , Raoof S. , Zheng Y. , Feng Z. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2025-06-03 00:00:00.0; 34(6), p. 944-951.
PMID: 40208630
Related Citations

Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.
Authors: Raychaudhuri R. , Cheng H.H. , Gulati R. , Schweizer M.T. , Lin A. , Yezefski T. , Khan H.M. , Yu E.Y. , Hawley J.E. , Nelson P.S. , et al. .
Source: European Urology Oncology, 2025-05-23 00:00:00.0; , .
EPub date: 2025-05-23 00:00:00.0.
PMID: 40413129
Related Citations

Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Active Lifestyle Study.
Authors: Schenk J.M. , Gulati R. , Beatty S.J. , Plymate S. , Lin D.W. , Dash A. , Porter M.P. , Vandoren M. , Wright J.L. , Neuhouser M.L. .
Source: Journal Of The National Cancer Institute, 2025-05-10 00:00:00.0; , .
EPub date: 2025-05-10 00:00:00.0.
PMID: 40347455
Related Citations

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after ¹⁷⁷Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
Authors: Raychaudhuri R. , Tuchayi A.M. , Low S.K. , Arafa A.T. , Graham L.S. , Gulati R. , Pritchard C.C. , Montgomery R.B. , Haffner M.C. , Nelson P.S. , et al. .
Source: European Urology Oncology, 2025-02-06 00:00:00.0; , .
EPub date: 2025-02-06 00:00:00.0.
PMID: 39920014
Related Citations

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening.
Authors: Chung D.H. , Caverly T.J. , Schipper M.J. , Hofer T.P. , Gulati R. , Rose B.S. , Caram M.E.V. , Tsao P.A. , Stensland K.D. , Elliott D. , et al. .
Source: Jama Network Open, 2025-02-03 00:00:00.0; 8(2), p. e2459766.
EPub date: 2025-02-03 00:00:00.0.
PMID: 39951264
Related Citations

Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.
Authors: Goddard K.A.B. , Feuer E.J. , Mandelblatt J.S. , Meza R. , Holford T.R. , Jeon J. , Lansdorp-Vogelaar I. , Gulati R. , Stout N.K. , Howlader N. , et al. .
Source: Jama Oncology, 2025-02-01 00:00:00.0; 11(2), p. 162-167.
PMID: 39636625
Related Citations

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received ¹⁷⁷Lu-PSMA-617: Importance of ¹⁸F-FDG-Avid Discordant Findings.
Authors: Demirci R.A. , Ghodsi A. , Gulati R. , Behnia S. , Nelson P.S. , Cheng H.H. , Yezefski T.A. , Haffner M.C. , Hawley J.E. , Montgomery R.B. , et al. .
Source: Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine, 2025-01-03 00:00:00.0; 66(1), p. 47-53.
EPub date: 2025-01-03 00:00:00.0.
PMID: 39542703
Related Citations

Multi-Cancer Early Detection Tests: State of the Art and Implications for Radiologists.
Authors: Kang S.K. , Gulati R. , Moise N. , Hur C. , Elkin E.B. .
Source: Radiology, 2025 Jan; 314(1), p. e233448.
PMID: 39807974
Related Citations

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving ¹⁷⁷Lu-PSMA-617.
Authors: Demirci R.A. , Gulati R. , Hawley J.E. , Yezefski T. , Haffner M.C. , Cheng H.H. , Montgomery R.B. , Schweizer M.T. , Yu E.Y. , Nelson P.S. , et al. .
Source: Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine, 2024-12-03 00:00:00.0; 65(12), p. 1945-1951.
EPub date: 2024-12-03 00:00:00.0.
PMID: 39510589
Related Citations

Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
Authors: Zhao Y. , Gulati R. , Yang Z. , Newcomb L. , Zheng Y. , Zhu K. , Liu M. , Heijnsdijk E.A.M. , Haffner M.C. , Cooperberg M. , et al. .
Source: Journal Of The National Cancer Institute, 2024-11-20 00:00:00.0; , .
EPub date: 2024-11-20 00:00:00.0.
PMID: 39565901
Related Citations

Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019.
Authors: Owens L. , Brahme O. , Gulati R. , Etzioni R. .
Source: Jnci Cancer Spectrum, 2024-11-01 00:00:00.0; 8(6), .
PMID: 39441819
Related Citations

Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial.
Authors: Raychaudhuri R. , DeJong M. , Rettig M. , Yu E.Y. , Gulati R. , Schweizer M.T. , Nelson P.S. , Pritchard C.C. , Montgomery B. , Cheng H.H. .
Source: European Urology, 2024-06-17 00:00:00.0; , .
EPub date: 2024-06-17 00:00:00.0.
PMID: 38890069
Related Citations

Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.
Authors: Gulati R. , Jiao B. , Al-Faouri R. , Sharma V. , Kaul S. , Fleishman A. , Wymer K. , Boorjian S.A. , Olumi A.F. , Etzioni R. , et al. .
Source: Annals Of Internal Medicine, 2024-06-04 00:00:00.0; , .
EPub date: 2024-06-04 00:00:00.0.
PMID: 38830219
Related Citations

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates.
Authors: Ajkunic A. , Sayar E. , Roudier M.P. , Patel R.A. , Coleman I.M. , De Sarkar N. , Hanratty B. , Adil M. , Zhao J. , Zaidi S. , et al. .
Source: Npj Precision Oncology, 2024-05-17 00:00:00.0; 8(1), p. 104.
EPub date: 2024-05-17 00:00:00.0.
PMID: 38760413
Related Citations

Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
Authors: Lee K.M. , Nelson T.J. , Bryant A. , Teerlink C.C. , Gulati R. , Pagadala M.S. , Tcheandjieu C. , Pridgen K.M. , DuVall S.L. , Yamoah K. , et al. .
Source: Journal Of The National Cancer Institute, 2024-05-08 00:00:00.0; 116(5), p. 753-757.
PMID: 38212986
Related Citations

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Authors: Raychaudhuri R. , Mo G. , Tuchayi A.M. , Graham L. , Gulati R. , Pritchard C.C. , Haffner M.C. , Yezefski T. , Hawley J.E. , Cheng H.H. , et al. .
Source: Jco Precision Oncology, 2024 Apr; 8, p. e2300634.
PMID: 38662984
Related Citations

Projecting the impact of multi-cancer early detection on late-stage incidence using multi-state disease modeling.
Authors: Lange J.M. , Gogebakan K.C. , Gulati R. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2024-03-20 00:00:00.0; , .
EPub date: 2024-03-20 00:00:00.0.
PMID: 38506751
Related Citations

The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
Authors: Wright J.L. , Schenk J.M. , Gulati R. , Beatty S.J. , VanDoren M. , Lin D.W. , Porter M.P. , Morrissey C. , Dash A. , Gore J.L. , et al. .
Source: Cancer, 2024-02-14 00:00:00.0; , .
EPub date: 2024-02-14 00:00:00.0.
PMID: 38353455
Related Citations

ASSESSMENT OF CELL SURFACE TARGETS IN METASTATIC PROSTATE CANCER: EXPRESSION LANDSCAPE AND MOLECULAR CORRELATES.
Authors: Ajkunic A. , Sayar E. , Roudier M.P. , Patel R.A. , Coleman I.M. , De Sarkar N. , Hanratty B. , Adil M. , Zhao J. , Zaidi S. , et al. .
Source: Research Square, 2023-12-19 00:00:00.0; , .
EPub date: 2023-12-19 00:00:00.0.
PMID: 38196594
Related Citations

Quantifying the potential benefits of early detection for pancreatic cancer through a counterfactual simulation modeling analysis.
Authors: Park J. , Lim F. , Prest M. , Ferris J.S. , Aziz Z. , Agyekum A. , Wagner S. , Gulati R. , Hur C. .
Source: Scientific Reports, 2023-11-16 00:00:00.0; 13(1), p. 20028.
EPub date: 2023-11-16 00:00:00.0.
PMID: 37973858
Related Citations

Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors.
Authors: Gulati R. , Nyame Y.A. , Lange J.M. , Shoag J.E. , Tsodikov A. , Etzioni R. .
Source: Journal Of The National Cancer Institute. Monographs, 2023-11-08 00:00:00.0; 2023(62), p. 212-218.
PMID: 37947332
Related Citations

Revisiting the Standard Blueprint for Biomarker Development to Address Emerging Cancer Early Detection Technologies.
Authors: Etzioni R. , Gulati R. , Patriotis C. , Rutter C. , Zheng Y. , Srivastava S. , Feng Z. .
Source: Journal Of The National Cancer Institute, 2023-11-06 00:00:00.0; , .
EPub date: 2023-11-06 00:00:00.0.
PMID: 37941446
Related Citations

Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
Authors: Patel R.A. , Sayar E. , Coleman I. , Roudier M.P. , Hanratty B. , Low J.Y. , Jaiswal N. , Ajkunic A. , Dumpit R. , Ercan C. , et al. .
Source: The Journal Of Pathology, 2023-10-18 00:00:00.0; , .
EPub date: 2023-10-18 00:00:00.0.
PMID: 37850574
Related Citations

Benefits and harms of prostate specific antigen testing according to Australian guidelines.
Authors: Caruana M. , Gulati R. , Etzioni R. , Barratt A. , Armstrong B.K. , Chiam K. , Nair-Shalliker V. , Luo Q. , Bang A. , Grogan P. , et al. .
Source: International Journal Of Cancer, 2023-10-11 00:00:00.0; , .
EPub date: 2023-10-11 00:00:00.0.
PMID: 37819139
Related Citations

Prostate Cancer Screening in African American Men: A Review of the Evidence.
Authors: Kensler K.H. , Johnson R. , Morley F. , Albrair M. , Dickerman B.A. , Gulati R. , Holt S.K. , Iyer H.S. , Kibel A.S. , Lee J.R. , et al. .
Source: Journal Of The National Cancer Institute, 2023-09-15 00:00:00.0; , .
EPub date: 2023-09-15 00:00:00.0.
PMID: 37713266
Related Citations

Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?
Authors: Owens L. , Gogebakan K.C. , Menon U. , Gulati R. , Weiss N.S. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2023-06-01 00:00:00.0; 32(6), p. 741-743.
PMID: 37259797
Related Citations

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Authors: Bhatia V. , Kamat N.V. , Pariva T.E. , Wu L.T. , Tsao A. , Sasaki K. , Sun H. , Javier G. , Nutt S. , Coleman I. , et al. .
Source: Nature Communications, 2023-04-11 00:00:00.0; 14(1), p. 2041.
EPub date: 2023-04-11 00:00:00.0.
PMID: 37041154
Related Citations

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer.
Authors: Sayar E. , Patel R.A. , Coleman I.M. , Roudier M.P. , Zhang A. , Mustafi P. , Low J.Y. , Hanratty B. , Ang L.S. , Bhatia V. , et al. .
Source: Jci Insight, 2023-02-23 00:00:00.0; , .
EPub date: 2023-02-23 00:00:00.0.
PMID: 36821396
Related Citations

Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
Authors: Schweizer M.T. , True L. , Gulati R. , Zhao Y. , Ellis W. , Schade G. , Montgomery B. , Goyal S. , Nega K. , Hakansson A.K. , et al. .
Source: The Journal Of Urology, 2023 Feb; 209(2), p. 354-363.
EPub date: 2023-02-01 00:00:00.0.
PMID: 36621991
Related Citations

Reply by Authors.
Authors: Schweizer M.T. , True L. , Gulati R. , Zhao Y. , Ellis W. , Schade G. , Montgomery B. , Goyal S. , Nega K. , Hakansson A.K. , et al. .
Source: The Journal Of Urology, 2023 Feb; 209(2), p. 362-363.
EPub date: 2023-02-01 00:00:00.0.
PMID: 36621992
Related Citations

Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
Authors: Cheng H.H. , Sokolova A.O. , Gulati R. , Bowen D. , Knerr S.A. , Klemfuss N. , Grivas P. , Hsieh A. , Lee J.K. , Schweizer M.T. , et al. .
Source: Jco Precision Oncology, 2023 Jan; 7, p. e2200104.
PMID: 36623239
Related Citations

Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Authors: Schweizer M.T. , Gulati R. , Yezefski T. , Cheng H.H. , Mostaghel E. , Haffner M.C. , Patel R.A. , De Sarkar N. , Ha G. , Dumpit R. , et al. .
Source: Prostate Cancer And Prostatic Diseases, 2022-12-23 00:00:00.0; , .
EPub date: 2022-12-23 00:00:00.0.
PMID: 36564459
Related Citations

Reducing Prostate Cancer Overdiagnosis.
Authors: Gulati R. .
Source: The New England Journal Of Medicine, 2022-12-08 00:00:00.0; 387(23), p. 2187-2188.
PMID: 36477037
Related Citations

Clonal Relationships of Adjacent Gleason Pattern 3 and Gleason Pattern 5 Lesions in Gleason Scores 3+5=8 and 5+3=8.
Authors: Bakbak H. , Sayar E. , Kaur H.B. , Salles D.C. , Patel R.A. , Hicks J. , Lotan T.L. , De Marzo A.M. , Gulati R. , Epstein J.I. , et al. .
Source: Human Pathology, 2022-10-26 00:00:00.0; , .
EPub date: 2022-10-26 00:00:00.0.
PMID: 36309296
Related Citations

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Authors: Keeney E. , Sanghera S. , Martin R.M. , Gulati R. , Wiklund F. , Walsh E.I. , Donovan J.L. , Hamdy F. , Neal D.E. , Lane J.A. , et al. .
Source: Pharmacoeconomics, 2022-10-06 00:00:00.0; , .
EPub date: 2022-10-06 00:00:00.0.
PMID: 36201131
Related Citations

Editorial Comment.
Authors: Gulati R. , Nyame Y.A. .
Source: The Journal Of Urology, 2022-09-06 00:00:00.0; , p. 101097JU000000000000283504.
EPub date: 2022-09-06 00:00:00.0.
PMID: 36065679
Related Citations

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Authors: Coleman I.M. , DeSarkar N. , Morrissey C. , Xin L. , Roudier M.P. , Sayar E. , Li D. , Corey E. , Haffner M.C. , Nelson P.S. .
Source: Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research, 2022-07-15 00:00:00.0; 28(14), p. 3127-3140.
PMID: 35552660
Related Citations

Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
Authors: Owens L. , Gulati R. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2022-07-01 00:00:00.0; 31(7), p. 1298-1304.
PMID: 35477176
Related Citations

Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.
Authors: Basourakos S.P. , Gulati R. , Vince R.A. , Spratt D.E. , Lewicki P.J. , Hill A. , Nyame Y.A. , Cullen J. , Markt S.C. , Barbieri C.E. , et al. .
Source: Nejm Evidence, 2022 Jun; 1(6), .
EPub date: 2022-05-15 00:00:00.0.
PMID: 35721307
Related Citations

Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas.
Authors: Heijnsdijk E.A.M. , Gulati R. , Lange J.M. , Tsodikov A. , Roberts R. , Etzioni R. .
Source: Jama Health Forum, 2022 05; 3(5), p. e221116.
EPub date: 2022-05-20 00:00:00.0.
PMID: 35977253
Related Citations

Inherited TP53 Variants and Risk of Prostate Cancer.
Authors: Maxwell K.N. , Cheng H.H. , Powers J. , Gulati R. , Ledet E.M. , Morrison C. , Le A. , Hausler R. , Stopfer J. , Hyman S. , et al. .
Source: European Urology, 2022 Mar; 81(3), p. 243-250.
EPub date: 2021-12-01 00:00:00.0.
PMID: 34863587
Related Citations

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
Authors: De Sarkar N. , Dasgupta S. , Chatterjee P. , Coleman I. , Ha G. , Ang L.S. , Kohlbrenner E.A. , Frank S.B. , Nunez T.A. , Salipante S.J. , et al. .
Source: Jci Insight, 2021-12-08 00:00:00.0; 6(23), .
EPub date: 2021-12-08 00:00:00.0.
PMID: 34877933
Related Citations

A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis.
Authors: Psutka S.P. , Gulati R. , Jewett M.A.S. , Fadaak K. , Finelli A. , Legere L. , Morgan T.M. , Pierorazio P.M. , Allaf M.E. , Herrin J. , et al. .
Source: European Urology, 2021-11-30 00:00:00.0; , .
EPub date: 2021-11-30 00:00:00.0.
PMID: 34862099
Related Citations

A Quantitative Framework to Study Potential Benefits and Harms of Multi-cancer Early Detection Testing.
Authors: Jiao B. , Gulati R. , Katki H.A. , Castle P.E. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2021-09-20 00:00:00.0; , .
EPub date: 2021-09-20 00:00:00.0.
PMID: 34548329
Related Citations